NasdaqGS:TARSPharmaceuticals
Tarsus Pharmaceuticals (TARS): Losses Deepen 39.9% Annually, Bullish Growth Narrative Faces Profitability Test
Tarsus Pharmaceuticals (TARS) remains unprofitable, with annual losses having deepened at a rate of 39.9% per year over the past five years and no improvement in net profit margins in the latest period. Looking forward, revenue is forecast to grow 20.8% per year, outpacing the broader US market’s 10.5% growth. Earnings are projected to surge 115.27% annually, positioning the company for a potential move to profitability within the next three years. Investors watching Tarsus are weighing these...